11 / 12
Page 31
Notes:
allied
academies
Nov 22-23, 2018 | Paris, France
Joint Event
Nutrition and Health
16
th
International Conference on
26
th
International Conference on
Diabetes and Endocrinology
&
Journal of Insights in Nutrition and Metabolism | Volume 2
Serge P Bottari
Alps University Medical School and Hospital, France
Serum IRAP, a novel direct biomarker of insulin-resistance as a screening, diagnostic and drug
discovery tool
I
nsulin resistance (IR) affects more than half of the adult
population worldwide. Type 2 diabetes (T2D), which often
follows in the absence of treatment, affects more than
400 million people and represents more than 10 % of the
health budget in industrialized countries. A preventive public
health policy is urgently needed to stop this constantly
progressing epidemic. Indeed, early management of IR
does not only strongly reduce its evolution towards T2D
but also strongly reduces the appearance of cardiovascular
comorbidity as well as that of associated cancers. There is
however currently no simple and reliable test available for
the diagnosis or screening of IR. We therefore developed
an ELISA for the quantitative determination of a novel
circulating biomarker of IR, IRAP. IRAP is associated with
and translocated in a stoechiometric fashion together with
GLUT4 to the plasma membrane in response to insulin in
skeletal muscle and adipose tissue. Its extracellular domain
is subsequently cleaved and secreted in the blood stream.
In T2D, IRAP translocation in response to insulin is strongly
decreased. Our patented sandwich ELISA is highly sensitive
and specific, robust and very cost effective. Results of pilot
studies indicate an excellent correlation between serum
IRAP levels and insulin sensitivity. We therefore believe that
serum IRAP is a direct marker of insulin sensitivity and that
the quantitative determination of its plasma levels should
allow large scale screening of populations at risk for IR and
T2D, thereby allowing the enforcement of a preventive health
policy aiming at reducing this epidemic. Similarly, simple
companion tests allowing the assessment of the efficacy
of novel drugs aimed at improving insulin sensitivity do not
exist yet. As such serum IRAP appears as a useful alternative
to the euglycemic hyperinsulinic clamp which is very tedious,
expensive and requires experienced teams, tomonitor insulin
sensitivity in human in clinical trials and therapeutic trials.
Speaker Biography
Serge P Bottari obtained his MD and PhD at the Free University Brussels, Belgium. He
specialized in OB/GYN and Biochemistry and was a post-doctoral fellow and research
associate at UC San Francisco. After having been a project leader at Sandoz and CIBA
Geigy in Basel (Switzerland), he became professor of cell biology at the Medical School
in Grenoble and head of endocrine biology in 1993. His articles in premium journals
have been cited over 4000 times and he is a member of several editorial boards. He
also holds several patents. His h-index is 31. His current work focuses among others on
the molecular mechanisms involved in insulin resistance and on the development of
novel diagnostic tools.
e:
serge.bottari@univ-grenoble-alpes.fr